Backbone tech innovators elliquence and Implanet to exhibit at NASS in Chicago, September 25-28, 2024 (elliquence LLC Sales space 2419 Implanet Sales space 2412)
September 25, 2024 /OrthoSpineNews/ – elliquence LLC, specializing in superior minimally invasive surgical applied sciences, and Implanet (Euronext Progress: ALIMP, FR0013470168, eligible for PEA-PME), a medical know-how firm specializing in implants for orthopedic surgical procedure and the distribution of superior medical gear, have collectively introduced a strategic settlement for distribution of Implanet’s Ultrasonic Bone Scalpel in endoscopic spine surgical procedure. The announcement is being made on the North American Backbone Society (NASS) Annual Assembly, the place each corporations are showcasing their newest applied sciences.
elliquence’s Surgi-Max Extremely platform is well known for delivering efficient tender tissue dissection and coagulation in endoscopic procedures, whereas Implanet’s Olea know-how permits exact and environment friendly bone slicing. By combining the precision of Implanet’s ultrasonic bone scalpel with elliquence’s well-established Surgi-Max Extremely radiofrequency and its bipolar Set off-Flex know-how, surgeons are actually geared up with a novel synergy of bone and tender tissue administration instruments. Integrating the ultrasonic bone scalpel permits for safer, extra managed bone removing, preserving neural buildings and minimizing tender tissue injury—additional enhancing the precision and outcomes of minimally invasive spine surgical procedure.
“We’re honored to be participating with our like-minded colleagues to additional introduce the surgeon group to first-of-its-kind endoscopic blade know-how,” said Max Painter, Vice President and Basic Supervisor of Implanet America. “It’s rewarding to have the ability to staff with different innovation-driven corporations to develop the attain of this progressive know-how and supply the broader surgeon group with game-changing options.”
“This partnership is an endorsement of the medical worth of our know-how,” added Ludovic Lastennet, Implanet’s Chief Government Officer. “This sort of partnership suits with the medium-term growth plan we introduced in the course of 2023 and the partnership with SanYou Medical. It demonstrates our skill to market new applied sciences with a newly shaped seasoned staff within the US. With this staff on board, we can be in a position to launch new mainstream product strains within the brief time period.”
About elliquence, LLC.
elliquence, LLC is a number one medical system firm based mostly in New York, specializing in superior minimally invasive surgical applied sciences. With over 50 years of innovation, Elliquence is acknowledged globally for its Surgi-Max Extremely radiofrequency platform, which supplies surgeons with unparalleled precision in tender tissue dissection and coagulation. The corporate’s mission is to companion with the medical group to develop high-quality, cost-effective options that improve affected person outcomes whereas decreasing procedural dangers and restoration occasions. elliquence’s cutting-edge applied sciences are extensively utilized in endoscopic spine surgical procedure, orthopedics, neurosurgery, and ache administration. Recognized for pushing the boundaries of surgical innovation, Elliquence continues to steer the cost in bettering the effectivity and effectiveness of minimally invasive procedures.
For additional info, please go to www.elliquence.com
About IMPLANET
Based in 2007, IMPLANET is a medical know-how firm that manufactures high-quality implants for orthopedic surgical procedure and distributing medical know-how gear. Its exercise revolves round a complete progressive resolution for bettering the remedy of spinal pathologies (JAZZ®) complemented by the product vary provided by Orthopaedic & Backbone Improvement (OSD), acquired in Might 2021 (thoraco-lumbar screws, cages and cervical plates). Implanet’s tried-and-tested orthopedic platform is predicated on the traceability of its merchandise. Protected by 4 households of worldwide patents, JAZZ® has obtained 510(ok) regulatory clearance from the Food and Drug Administration (FDA) in america, the CE mark in Europe and ANVISA approval in Brazil. In 2022, IMPLANET entered right into a industrial, technological and monetary partnership with SANYOU MEDICAL, China’s second largest medical system producer. IMPLANET employs 43 employees and recorded a consolidated income of €7.4 million in 2023. Based mostly close to Bordeaux in France, IMPLANET opened a US subsidiary in Boston in 2013. IMPLANET is listed on the Euronext Progress market in Paris.
For additional info, please go to www.Implanet.com.
USA Media Contact
Paul Williams
310-569-0023
paul@medialinecommunications.com
Discussion about this post